196808-24-9 Usage
Description
GW1929 is a non-thiazolidinedione activator of Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a nuclear receptor that regulates fatty acid storage and glucose metabolism. It binds with a Ki value of 1.4 nM, showing greater than 1,000-fold selectivity over other PPAR subtypes. GW1929 exhibits anti-hyperglycemic and anti-hyperlipidemic activity in mouse and rat models of type 2 diabetes, with effects surpassing those of troglitazone. Additionally, it possesses neuroprotective properties in global cerebral ischemic-reperfusion injury, reducing inflammation and apoptotic DNA fragmentation.
Uses
Used in Pharmaceutical Research:
GW1929 is used as a PPARγ ligand for studying its effects on various biological processes and diseases.
Used in Adipogenesis Research:
GW1929 is used as a PPARγ ligand to study its effects on plant homeodomain finger protein 16 (Phf16) and patatin-like phospholipase domain containing 3 (Pnpla3) expression, which are involved in adipogenesis.
Used in Human Hepatoma Cells:
GW1929 is used as a PPARγ activator to study its effects on complement component 3 (C3) gene expression in human hepatoma cells.
Used in Human Breast Cancer Cells:
GW1929 is used as a PPARγ activator in human breast cancer cells to investigate its potential therapeutic effects and mechanisms of action.
Biological Activity
Highly selective orally active peroxisome proliferator-activated receptor (PPAR) γ agonist (pEC 50 values are 8.05, < 4 and < 4 for human PPAR γ , PPAR α and PPAR δ receptors respectively). Decreases glucose, fatty acid and triglyceride levels following oral administration in vivo .
Biochem/physiol Actions
GW1929 is a non-thiazolidinedione and is involved in cell growth inhibition and regulating gene expression. It exhibits neuroprotective effects against global cerebral ischemic-reperfusion injury by DNA fragmentation and minimizing the inflammation. GW1929 participates in the inhibition of α7 N-acetylcholine receptor expression and promoter activity. It also influences the early growth response-1 (Egr-1) protein expression.
in vitro
gw1929 was tested on currents through l-type voltage-dependent calcium channels (vdcc) in freshly isolated smooth muscle cells. using ba2+ as the charge carrier through vdcc, the ic50s for gw1929 and pioglitazone were determined to be 5.0 +/- 0.7 and 10.0 +/- 0.8 μm, respectively. gw1929 and pioglitazone were both effective on inhibiting vdcc and relaxing pressurized arteries, indicating the vasodilation of resistance arteries might be explained by the inhibition of calcium entry through vdcc [1].
in vivo
gw1929 treatment attenuated the neurological damage in focal cerebral ir injury significantly. in addition, the neuroprotective effects of gw1929 were found to be associated with significant reduction in the levels of mmp-9, cox-2, inos, tnfα and il-6. neuroprotective effects of gw1929 related with significant reduction in tunel positive cells in ir challenged brain [2].
IC 50
5.0 μm
references
[1] heppner tj,bonev ad,eckman dm,gomez mf,petkov gv,nelson mt. novel ppargamma agonists gi 262570, gw 7845, gw 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. pharmacology.2005 jan;73(1):15-22. [2] kaundal rk,sharma ss. ameliorative effects of gw1929, a nonthiazolidinedione pparγ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. curr neurovasc res.2011 aug 1;8(3):236-45.
Check Digit Verification of cas no
The CAS Registry Mumber 196808-24-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,8,0 and 8 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 196808-24:
(8*1)+(7*9)+(6*6)+(5*8)+(4*0)+(3*8)+(2*2)+(1*4)=179
179 % 10 = 9
So 196808-24-9 is a valid CAS Registry Number.
InChI:InChI=1/C30H29N3O4/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23/h2-18,27,32H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
196808-24-9Relevant articles and documents
N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents
Henke, Brad R.,Blanchard, Steven G.,Brackeen, Marcus F.,Brown, Kathleen K.,Cobb, Jeff E.,Collins, Jon L.,Harrington Jr., W. Wallace,Hashim, Mir A.,Hull-Ryde, Emily A.,Kaldor, Istvan,Kliewer, Steven A.,Lake, Debra H.,Leesnitzer, Lisa M.,Lehmann, Jürgen M.,Lenhard, James M.,Orband-Miller, Lisa A.,Miller, John F.,Mook Jr., Robert A.,Noble, Stewart A.,Oliver Jr., William,Parks, Derek J.,Plunket, Kelli D.,Szewczyk, Jerzy R.,Willson, Timothy M.
, p. 5020 - 5036 (2007/10/03)
We have identified a novel series of antidiabetic N-(2-benzoylphenyl)- L-tyrosine derivatives which are potent, selective PPARγ agonists. Through the use of in vitro PPARγ binding and functional assays (2S)-3-(4- (benzyloxy)phenyl)-2-((1-methyl-3-oxo-3-ph
